Progenity is the laughing stock of NIPT. They don't have any of their own algorithms or testing methodologies. They simply leach off other platforms and repackage it. No in-house studies from their own lab on clinical outcomes, they rely on other labs to do that for them and pass it off as their own. Competitors are eating their lunch. Most importantly they have extremely illegal billing practices that once OIG starts regulating lab companies will shut them down. But hey, a paycheck is a paycheck! Good luck selling against the likes of Roche and Natera.